Randomised, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke.
Phase of Trial: Phase I
Latest Information Update: 24 Sep 2010
At a glance
- Drugs Lu AA 24493 (Primary)
- Indications Stroke
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Lundbeck A/S
- 31 Aug 2018 Biomarkers information updated
- 31 Dec 2008 End date added from ClinicalTrials.gov.
- 31 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.